2.507-oral-Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).2020 ASCO.
结果显示,总人群的客观缓解率(ORR)达到 29%(95%CI:18.7%～41.2%),疾病控制率(DCR)达到 58%。 a Summary of the category of the bestresponse in each arm of the FUTURE trial.b Duration of treatment in the FUTURE andof the last previous therapy in 18 patients in the PP population with availab...
结果显示,总人群的客观缓解率(ORR)达到 29%(95%CI:18.7%～41.2%),疾病控制率(DCR)达到 58%。 a Summary of the category of the bestresponse in each arm of the FUTURE trial.b Duration of treatment in the FUTURE andof ...
结果显示,总人群的客观缓解率(ORR)达到 29%(95%CI:18.7%～41.2%),疾病控制率(DCR)达到 58%。 a Summary of the category of the bestresponse in each arm of the FUTURE trial.b Duration of treatment in the FUTURE andof the last previous therapy in 18 patients in the PP population with availab...
a Summary of the category of the bestresponse in each arm of the FUTURE trial.b Duration of treatment in the FUTURE andof the last previous therapy in 18 patients in the PP population with availableprevious treatment duration information.c, f Best percentage change from baselinein the sum of...
Methods: Patients from the SYSUCC-001 trial, randomized to standard treatment with or without metronomic capecitabine maintenance, were pooled. Candidate covariates included age, tumor size, lymph node, histological grade, Ki-67 percentage, lymphovascular invasion, chemotherapy regimen and capecitabine ...
a Summary of the category of the bestresponse in each arm of the FUTURE trial.b Duration of treatment in the FUTURE andof the last previous therapy in 18 patients in the PP population with availableprevious treatment duration information.c, f Best percentage change from baselinein the sum of...